Yamashita Takeshi, Sugimori Chiharu, Ishiyama Ken, Yamazaki Hirohito, Okumura Hirokazu, Kondo Yukio, Takami Akiyoshi, Nakao Shinji
Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, 920-8641, Japan.
Int J Hematol. 2009 Mar;89(2):238-242. doi: 10.1007/s12185-008-0234-9. Epub 2008 Dec 25.
Patients with severe infections are thought to be ineligible for cord blood stem cell transplantation (CBT) because the conventional 5-6 day-conditioning regimens potentially makes them susceptible to fatal infections by the time neutrophil engraftment occurs. Two patients were treated with minimum conditioning regimens consisting of 30 mg/m(2) fludarabin (Flu) and 2 g/m(2) cyclophosphamide (CY) on day-1 and total body irradiation (TBI) of 2 or 4 Gy on day -1 or 0 followed by single unit CBT. The reasons for adopting such weak regimen were febrile neutropenia due to the rejection of the first cord blood (CB) graft given to a patient with follicular lymphoma resistant to chemotherapy and pulmonary aspergillosis in another patient with AML who relapsed after CBT. The AML patient received 40 mg/m(2) of melphalan on day-2 to reduce the leukemia burden. Both patients achieved 100% donor chimerism by day 19 and day 20 after CBT without an apparent exacerbation of the infections and remained in remission at 23 and 18 months after the CBT. These findings suggest that the 1-2 day regimens excluding antihuman thymocyte globulin may be sufficiently potent to ensure engraftment of CB in immunocompromised patients and safely administered even when patients are complicated by active infections.
重度感染患者被认为不适合进行脐血干细胞移植(CBT),因为传统的5 - 6天预处理方案可能使他们在中性粒细胞植入时易受致命感染。两名患者接受了最小预处理方案,包括在第1天给予30 mg/m²氟达拉滨(Flu)和2 g/m²环磷酰胺(CY),并在第1天或第0天给予2或4 Gy的全身照射(TBI),随后进行单单位CBT。采用如此弱的方案的原因是,一名对化疗耐药的滤泡性淋巴瘤患者首次脐血(CB)移植排斥导致发热性中性粒细胞减少,另一名急性髓系白血病(AML)患者在CBT后复发并患有肺曲霉病。AML患者在第2天接受40 mg/m²美法仑以减轻白血病负担。两名患者在CBT后第19天和第20天均实现了100%供体嵌合,感染无明显加重,并在CBT后23个月和18个月时仍处于缓解状态。这些发现表明,不包括抗人胸腺细胞球蛋白的1 - 2天预处理方案可能足以确保CB在免疫受损患者中植入,并且即使患者合并有活动性感染也能安全给药。